Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha
- 31 January 1992
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 28 (1) , 92-96
- https://doi.org/10.1016/0959-8049(92)90393-g
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.Journal of Clinical Oncology, 1989
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- The released interleukin 2 receptor binds interleukin 2 efficiently.The Journal of Immunology, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985